The objective of this study is to evaluate the safety, tolerability, and pharmacokinetics (PK) of S241656 and to determine the recommended dose for expansion (RDE) of S241656 in participants with relapsed/refractory (R/R) acute myeloid leukemia (AML), myelodysplastic syndrome/acute myeloid leukemia (MDS/AML), or chronic myelomonocytic leukemia (CMML). Part 1A dose escalation will determine the RDE to be used in a future expansion stage of the trial. An optional Part 1B drug-drug interaction (DDI) substudy will evaluate the effect of posaconazole on the PK of S241656.
The study consists of a screening period of up to 21 days, a treatment period consisting of continuous 28-day cycles of treatment, an end-of-treatment visit, a safety follow-up period, and long-term disease and survival follow-up every 3 months. Participants in the optional DDI substudy may continue treatment in the main study following completion of the DDI assessment period. Participants may undergo bone marrow aspirates and/or biopsies, blood tests, electrocardiograms (ECGs), echocardiograms or multigated acquisition (MUGA) scans, physical examinations, ophthalmologic assessments, and disease response questionnaires.
Eastern Cooperative Oncology Group (ECOG) performance status of ≤ 2.
Investigator-assessed life expectancy of ≥ 3 months.
Able and willing to comply with requirements of the study protocol.
Documented genetic characterization of the disease as per local practice.
Known hypersensitivity to S241656, or Posaconazole (Part 1B).
Pregnant or breastfeeding; positive serum pregnancy test for WOCBP.
Diagnosis of acute promyelocytic leukemia (French-American-British [FAB] M3 classification), MPN, mixed/ambiguous lineage, histiocytic/dendritic cell neoplasms, or AML with isolated extramedullary disease (no marrow/blood involvement).
Active Central Nervous System (CNS) disease (by cytologic or radiographic evidence).
Sequential
S241656
DrugTablets taken by mouth.
Posaconazole
DrugTablets taken by mouth
(Part 1A and 1B) Dose limiting toxicity (DLTs) associated with S241656 during the first cycle of treatment
(Part 1A and 1B) Number of Adverse Events (AEs)
(Part 1A and 1B) Number of Serious Adverse Events (SAEs)
(Part 1A and 1B) Severity of AEs
(Part 1A only) Cmax of S241656
(Part 1A only) Cmax of metabolite S243796
(Part 1A only) Tmax of S241656
(Part 1A only) Tmax of metabolite S243796
This trial is not recruiting at the moment. You can still explore other options:
